Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward
Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...
Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain
Rocket Pharmaceuticals' gene therapy treatments for rare diseases are promising. See why I think high cash burn and potential ...
Zawya19h
MIPIM Asia Summit 2024: Asia's Leading Platform for Real Estate Investment and Partnerships
The issuer is solely responsible for the content of this announcement.
13 Bizarre Christmas Laws You Never Knew Actually Existed
Christmas celebrates the birth of Christ, which one might think would make it a hands-down joyous occasion. Nope. Christmas ...
KitGuruTech on MSN4d
AMD RX 6700 XT is official - here's what we know!
Today AMD has announced its latest RDNA 2-based graphics card - the Radeon RX 6700 XT. We've only been given a high-level ...
Ensysce Biosciences Inc.: Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
Landmark Overdose Protection Clinical Trial of PF614-MPAR ~~ Expects Early Interim Data in 1Q 2025 ~ SAN DIEGO, CA / ACCESSWIRE / November 26, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" ...